261 related articles for article (PubMed ID: 33563576)
1. HLA-G/LILRBs: A Cancer Immunotherapy Challenge.
Carosella ED; Gregori S; Tronik-Le Roux D
Trends Cancer; 2021 May; 7(5):389-392. PubMed ID: 33563576
[TBL] [Abstract][Full Text] [Related]
2. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
[TBL] [Abstract][Full Text] [Related]
3. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.
Chen QY; Chen YX; Han QY; Zhang JG; Zhou WJ; Zhang X; Ye YH; Yan WH; Lin A
Front Immunol; 2021; 12():679090. PubMed ID: 34054869
[TBL] [Abstract][Full Text] [Related]
5. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
Binnewies M; Pollack JL; Rudolph J; Dash S; Abushawish M; Lee T; Jahchan NS; Canaday P; Lu E; Norng M; Mankikar S; Liu VM; Du X; Chen A; Mehta R; Palmer R; Juric V; Liang L; Baker KP; Reyno L; Krummel MF; Streuli M; Sriram V
Cell Rep; 2021 Oct; 37(3):109844. PubMed ID: 34686340
[TBL] [Abstract][Full Text] [Related]
6. Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary.
Schwich E; Hò GT; LeMaoult J; Bade-Döding C; Carosella ED; Horn PA; Rebmann V
Front Immunol; 2020; 11():2046. PubMed ID: 32973812
[TBL] [Abstract][Full Text] [Related]
7. Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy.
Leone RD; Powell JD
Cancer Immunol Res; 2021 Mar; 9(3):255-260. PubMed ID: 33648947
[TBL] [Abstract][Full Text] [Related]
8. CD8
Dumont C; Jacquier A; Verine J; Noel F; Goujon A; Wu CL; Hung TM; Desgrandchamps F; Culine S; Carosella ED; Rouas-Freiss N; LeMaoult J
Cancer Immunol Res; 2019 Oct; 7(10):1619-1632. PubMed ID: 31451484
[TBL] [Abstract][Full Text] [Related]
9. First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G.
Anna F; Bole-Richard E; LeMaoult J; Escande M; Lecomte M; Certoux JM; Souque P; Garnache F; Adotevi O; Langlade-Demoyen P; Loustau M; Caumartin J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737343
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
Front Immunol; 2021; 12():652160. PubMed ID: 33859645
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
12. The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?
Attia JVD; Dessens CE; van de Water R; Houvast RD; Kuppen PJK; Krijgsman D
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33213057
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
[TBL] [Abstract][Full Text] [Related]
14. Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma.
Fan J; Li J; Han J; Zhang Y; Gu A; Song F; Duan J; Yin D; Wang L; Yi Y
Mol Immunol; 2021 Aug; 136():82-97. PubMed ID: 34098344
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.
Lee JC; Mehdizadeh S; Smith J; Young A; Mufazalov IA; Mowery CT; Daud A; Bluestone JA
Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33008914
[TBL] [Abstract][Full Text] [Related]
16. Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment.
Wu D; Kuiaste I; Moreau P; Carosella E; Yotnda P
Oncotarget; 2015 Nov; 6(35):37385-97. PubMed ID: 26460949
[TBL] [Abstract][Full Text] [Related]
17. Tissue-resident memory CD8
Wang T; Shen Y; Luyten S; Yang Y; Jiang X
Pharmacol Res; 2020 Sep; 159():104876. PubMed ID: 32422340
[TBL] [Abstract][Full Text] [Related]
18. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
19. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
20. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
